American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

By L. Harris, H. Fritsche, R. Mennel, Larry Norton, P. Ravdin, S. Taube, M. Somerfield, D. Hayes, R. Bast. Journal of Oncology Practice, 2007

1,118 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c6c13ac409f9be521712e8d6fcc0f2b75df28b44

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Awareness and current knowledge of breast cancer (2017, background): “The different varieties displayed proof of clinical use and are suggested for utilization in practice [127].”
Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling (2011, methodology): “[15] Harris L, Fritsche H, Mennel R, et al.”
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype (2011, background): “In the past decade, many treatments undergoing clinical trials have been developed based on breast cancer molecular profiles.(11) However, one of the most promising therapy targets came with the identification of a pool of cancer cells with stem characteristicsdcancer stem cells (CSC).”
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011, neutral): “with newly diagnosed breast cancer (7).”
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. (2010, methodology): “Progesterone receptor (PgR) is also frequently measured for the management of breast cancer.(3) Initial reports, which have been validated through the years, suggested that patients with ER-positive/PgR-negative breast cancers have a worse prognosis than patients who have PgRpositive tumors.”
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry (2013, background): “The American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee did not advise the use of Ki-67 for prognosis in patients with newly identified breast cancer because of insufficient quality assurance [18].”
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “N0) breast cancer do not profit from comprehensive laboratory (including tumor markers [45]) and radiological staging [III, B].”
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010, methodology): “Progesterone receptor (PgR) is also frequently measured for the management of breast cancer.(3) Initial reports, which have been validated through the years, suggested that patients with ER-positive/PgR-negative breast cancers have a worse prognosis than patients who have PgRpositive tumors.”
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients (2010, background): “To date numerous additional genes have been suggested as being capable to predict prognosis in breast cancer [4].”
Cathepsin D--many functions of one aspartic protease. (2008, background): “[178] Harris L, Fritsche H, Mennel R, et al.”